Paper794496
Cancer treatment today and its impact on drug development, with special emphasis on the phase II clinical trial.
Carter SK. J Natl Cancer Inst, 1976. Cited by 46 papers, by iCite.
Cite this record
ConductScience Library. Cancer treatment today and its impact on drug development, with special emphasis on the phase II clinical trial. Papers, record 794496. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/794496
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cancer treatment today and its impact on drug development, with special emphasis on the phase II clinical trial.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Drug Evaluation | Major topic |
| Neoplasms | Major topic |
| Adult | |
| Brain Neoplasms | |
| Breast Neoplasms | |
| Child | |
| Female | |
| Head and Neck Neoplasms | |
| Humans | |
| Intestinal Neoplasms | |
| Intestine, Large | |
| Leukemia | |
| Lung Neoplasms | |
| Male | |
| Melanoma | |
| Ovarian Neoplasms | |
| Pancreatic Neoplasms | |
| Stomach Neoplasms | |
| Testicular Neoplasms | |
| Urogenital Neoplasms | |
| Uterine Neoplasms |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 15298732 | Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. | Cancer Sci | 2004 | https://conductscience.org/library/papers/15298732 | PubMed |
| 8071118 | Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer. | Jpn J Cancer Res | 1994 | https://conductscience.org/library/papers/8071118 | PubMed |
| 7173718 | Pyrimidine nucleoside phosphorylase activity in tumour and matched normal gastrointestinal mucosa. | Gut | 1982 | https://conductscience.org/library/papers/7173718 | PubMed |
| 7002528 | Cancer chemotherapy: new developments and changing concepts. | Drugs | 1980 | https://conductscience.org/library/papers/7002528 | PubMed |
| 6182702 | Palliative and adjunctive measures in rectal cancer. | World J Surg | 1982 | https://conductscience.org/library/papers/6182702 | PubMed |
| 2824273 | Biological features and chemosensitivity of human colorectal cancer xenografted in nude mice. | Gastroenterol Jpn | 1987 | https://conductscience.org/library/papers/2824273 | PubMed |
| 1537070 | 5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole. | Cancer Chemother Pharmacol | 1992 | https://conductscience.org/library/papers/1537070 | PubMed |
| 750106 | The clinical evaluation of analogues. I. The overall problem. | Cancer Chemother Pharmacol | 1978 | https://conductscience.org/library/papers/750106 | PubMed |
| 393428 | Mutagenic effects of some anticancer antibiotics. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/393428 | PubMed |
| 373904 | Cancer chemotherapy as it approaches middle age. | Cancer Chemother Pharmacol | 1978 | https://conductscience.org/library/papers/373904 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/794496
GET https://conductscience.org/api/papers/v1/794496/authors